Anzeige
❌
Mehr »
Sonntag, 25.10.2026 - Börsentäglich über 12.000 News
8 Millionen CAD eingesammelt, 21,45% Antimon entdeckt: Kanadas Bald-Hill-Projekt startet in die nächste Phase
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
CB

WKN: A2PGFW | ISIN: CNE100003F01 | Ticker-Symbol: CJH
Tradegate
22.10.26 | 08:13
3,260 Euro
+1,24 % +0,040
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
CANSINO BIOLOGICS INC Chart 1 Jahr
5-Tage-Chart
CANSINO BIOLOGICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,1803,26024.10.
3,1603,26023.10.

Aktuelle News zur CANSINO BIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.10.CANSINOBIO (06185): NOTICE OF BOARD MEETING7
24.09.Connecting Innovation and Global Markets: Jeanne Wang on CanSinoBIO's Next Stage of Growth15
17.09.CANSINOBIO (06185): 2026 INTERIM REPORT9
16.09.CANSINOBIO (06185): ANNOUNCEMENT ON THE GRANT OF RESERVED RESTRICTED SHARES UNDER THE 2025 A SHARE INCENTIVE SCHEME10
27.08.CanSino Biologics Inc: Overseas Growth Gathers Momentum as CanSinoBIO's Global Strategy Unlocks New Opportunities1.028HONG KONG, Aug 27, 2026 - (ACN Newswire) - CanSino Biologics Inc. ('CanSinoBIO,' 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of approximately...
► Artikel lesen
27.08.CANSINOBIO (06185): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 20268
26.08.CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - UPDATE ON MRNA TECHNOLOGY PLATFORM DEVELOPMENT14
CANSINO BIOLOGICS Aktie jetzt für 0€ handeln
20.08.CANSINOBIO (06185): INSIDE INFORMATION - NMPA OF CHINA GRANTS NDA APPROVAL TO TETANUS VACCINE13
17.08.Zulassungsantrag für Booster-Impfstoff treibt Aktie von CanSino Biologics an13
17.08.CanSino Biologics Inc: CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine Pipeline862HONG KONG, Aug 16, 2026 - (ACN Newswire) - On August 16, 2026, CanSino Biologics Inc. ("CanSinoBIO" HKEX: 06185/SHSE: 688185) announced that the New Drug Application (NDA) for its Tetanus, Reduced Diphtheria...
► Artikel lesen
14.08.CANSINOBIO (06185): NOTICE OF BOARD MEETING2
29.06.CanSino Biologics Inc: CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Further Expanding International Presence in South America734HONG KONG, June 29, 2026 - (ACN Newswire) - On June 25, CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) announced that the Company's ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)...
► Artikel lesen
25.06.CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - MCV4 OBTAINS DRUG REGISTRATION CERTIFICATE IN ARGENTINA-
10.06.CANSINOBIO (06185): ARTICLES OF ASSOCIATION1
10.06.CANSINOBIO (06185): POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION-
26.05.CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE I/II CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR PCV243
19.05.CANSINOBIO (06185): FORM OF PROXY FOR USE AT THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 10, 202612
19.05.CANSINOBIO (06185): NOTICE OF 2025 ANNUAL GENERAL MEETING14
19.05.CANSINOBIO (06185): 2025 AGM CIRCULAR-
11.05.CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - THE CENTER FOR DRUG EVALUATION, NMPA GRANTED PRIORITY REVIEW STATUS TO NDA FOR TD5CP ADOLESCENT AND ADULT3
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1